mitoxantrone has been researched along with Lymphoma, B-Cell in 30 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied." | 9.10 | Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas. ( Akiba, M; Bessho, M; Hirashima, K; Itoh, K; Itoh, Y; Kashimura, T; Kawai, N; Kishimoto, K; Matsuda, A; Murohashi, I; Sakata, T; Suzuki, T; Takahashi, T; Tominaga, K; Wakao, D; Yagasaki, F; Yoshida, K, 2002) |
| "Patients with histologically verified MALT lymphoma undergoing chemotherapy with MCP were evaluated retrospectively." | 5.32 | Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). ( Chott, A; Dirisamer, A; Drach, J; Hejna, M; Püspök, A; Raderer, M; Scheithauer, W; Wöhrer, S, 2003) |
| "Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied." | 5.10 | Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas. ( Akiba, M; Bessho, M; Hirashima, K; Itoh, K; Itoh, Y; Kashimura, T; Kawai, N; Kishimoto, K; Matsuda, A; Murohashi, I; Sakata, T; Suzuki, T; Takahashi, T; Tominaga, K; Wakao, D; Yagasaki, F; Yoshida, K, 2002) |
| " High-grade B-cell lymphoma, NOS (HGBL) have an aggressive clinical behavior and poor outcome using regimens currently employed for diffuse large B-cell lymphoma (DLBCL) such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)." | 3.88 | Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma. ( Bocchia, M; Cencini, E; Fabbri, A; Gentili, F; Mazzei, MA; Schiattone, L, 2018) |
| "Mitoxantrone (MTO) was further loaded into SAPC NP through hydrophobic interactions to obtain polysialylated immunogenic cell death (ICD) nanoinducer (MTO@SAPC NP)." | 1.72 | Polysialylated nanoinducer for precisely enhancing apoptosis and anti-tumor immune response in B-cell lymphoma. ( Guo, K; Li, S; Tong, R; Yin, X; Zhang, Q, 2022) |
| "Interestingly, in chronic lymphocytic leukemia (CLL) patients, we found that the patients with β2-microglobulin (β2-MG) < 3." | 1.42 | Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. ( Feng, X; Gu, Z; Li, F; Li, Z; Liu, W; Qi, J; Qiu, L; Xu, Y; Yi, S; Yu, Z; Zhan, F; Zou, D, 2015) |
| "Grade 3 follicular lymphoma (FL3) is thought to have an aggressive clinical course." | 1.32 | A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. ( Aoun, P; Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Greiner, TC; Hans, CP; Hock, LM; Lynch, JC; Vose, JM; Weisenburger, DD, 2003) |
| "Patients with histologically verified MALT lymphoma undergoing chemotherapy with MCP were evaluated retrospectively." | 1.32 | Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). ( Chott, A; Dirisamer, A; Drach, J; Hejna, M; Püspök, A; Raderer, M; Scheithauer, W; Wöhrer, S, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (10.00) | 18.2507 |
| 2000's | 21 (70.00) | 29.6817 |
| 2010's | 5 (16.67) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Q | 1 |
| Li, S | 1 |
| Guo, K | 1 |
| Yin, X | 1 |
| Tong, R | 1 |
| Cencini, E | 1 |
| Fabbri, A | 1 |
| Schiattone, L | 1 |
| Gentili, F | 1 |
| Mazzei, MA | 1 |
| Bocchia, M | 1 |
| Barrenetxea Lekue, C | 1 |
| Grasso Cicala, S | 1 |
| Leppä, S | 1 |
| Stauffer Larsen, T | 1 |
| Herráez Rodríguez, S | 1 |
| Alonso Caballero, C | 1 |
| Jørgensen, JM | 1 |
| Toldbod, H | 1 |
| Leal Martínez, I | 1 |
| D'Amore, F | 1 |
| Li, Z | 1 |
| Li, F | 1 |
| Yi, S | 1 |
| Gu, Z | 1 |
| Yu, Z | 1 |
| Xu, Y | 1 |
| Feng, X | 1 |
| Liu, W | 1 |
| Zou, D | 1 |
| Qi, J | 1 |
| Zhan, F | 1 |
| Qiu, L | 1 |
| Sakai, T | 1 |
| Masaki, Y | 1 |
| Otsuki, N | 1 |
| Sakamaki, I | 1 |
| Kishi, S | 1 |
| Miyazono, T | 1 |
| Urasaki, Y | 1 |
| Murakami, J | 1 |
| Satoh, T | 2 |
| Nakamura, T | 1 |
| Iwao, H | 1 |
| Nakajima, A | 1 |
| Kawanami, T | 1 |
| Miki, M | 1 |
| Fujita, Y | 1 |
| Tanaka, M | 1 |
| Fukushima, T | 1 |
| Okazaki, T | 1 |
| Ueda, T | 1 |
| Rieger, M | 1 |
| Österborg, A | 1 |
| Pettengell, R | 1 |
| White, D | 1 |
| Gill, D | 1 |
| Walewski, J | 1 |
| Kuhnt, E | 1 |
| Loeffler, M | 1 |
| Pfreundschuh, M | 1 |
| Ho, AD | 1 |
| Hans, CP | 1 |
| Weisenburger, DD | 1 |
| Vose, JM | 1 |
| Hock, LM | 1 |
| Lynch, JC | 1 |
| Aoun, P | 1 |
| Greiner, TC | 1 |
| Chan, WC | 1 |
| Bociek, RG | 1 |
| Bierman, PJ | 1 |
| Armitage, JO | 1 |
| Joyce, RM | 2 |
| Regan, M | 2 |
| Ottaway, J | 1 |
| Umiel, T | 2 |
| Tetreault, JC | 1 |
| Levine, J | 2 |
| McDermott, D | 2 |
| Hurley, D | 2 |
| Giallombardo, N | 2 |
| Smith, T | 1 |
| Lamontagne, D | 1 |
| Uhl, L | 2 |
| Avigan, D | 2 |
| Emmanouilides, C | 2 |
| Territo, M | 1 |
| Menco, H | 2 |
| Patel, R | 2 |
| Rosen, P | 2 |
| Wöhrer, S | 2 |
| Drach, J | 2 |
| Hejna, M | 2 |
| Scheithauer, W | 1 |
| Dirisamer, A | 1 |
| Püspök, A | 1 |
| Chott, A | 1 |
| Raderer, M | 2 |
| Ma, SY | 1 |
| Au, WY | 2 |
| Chim, CS | 1 |
| Lie, AK | 1 |
| Lam, CC | 1 |
| Tse, E | 1 |
| Leung, AY | 1 |
| Liang, R | 2 |
| Kwong, YL | 2 |
| Tokar, M | 1 |
| Rogachev, B | 1 |
| Levi, I | 1 |
| Yerushalmi, R | 1 |
| Ariad, S | 1 |
| Geffen, DB | 1 |
| Di Bella, N | 1 |
| Reynolds, C | 1 |
| Faragher, D | 1 |
| Muscato, J | 1 |
| Boehm, KA | 1 |
| Asmar, L | 1 |
| Bartsch, R | 1 |
| Otrock, ZK | 1 |
| Shamseddine, AI | 1 |
| Taher, AT | 1 |
| Chan, LC | 1 |
| Yokoyama, M | 1 |
| Kobayashi, T | 1 |
| Kubo, Y | 1 |
| Kageyama, Y | 1 |
| Kihara, K | 1 |
| Niitsu, N | 1 |
| Kohuri, M | 1 |
| Higashihara, M | 1 |
| Bessho, M | 2 |
| Sugimoto, T | 1 |
| Matano, S | 1 |
| Nishijima, H | 1 |
| Kakuta, K | 1 |
| Inamura, K | 1 |
| Okamura, T | 1 |
| Munemoto, S | 1 |
| Satoh, S | 1 |
| Tarella, C | 1 |
| Zanni, M | 1 |
| Di Nicola, M | 1 |
| Patti, C | 1 |
| Calvi, R | 1 |
| Pescarollo, A | 1 |
| Zoli, V | 1 |
| Fornari, A | 1 |
| Novero, D | 1 |
| Cabras, A | 1 |
| Stella, M | 1 |
| Comino, A | 1 |
| Remotti, D | 1 |
| Ponzoni, M | 1 |
| Caracciolo, D | 1 |
| Ladetto, M | 1 |
| Magni, M | 1 |
| Devizzi, L | 1 |
| Rosato, R | 1 |
| Boccadoro, M | 1 |
| Bregni, M | 1 |
| Corradini, P | 1 |
| Gallamini, A | 1 |
| Majolino, I | 1 |
| Mirto, S | 1 |
| Gianni, AM | 1 |
| Tsushima, K | 1 |
| Hizawa, Y | 1 |
| Nakui, Y | 1 |
| Itoh, J | 1 |
| Tamura, Y | 1 |
| Saitoh, S | 1 |
| Taka-mi, H | 1 |
| Munakata, A | 1 |
| Kawamura, S | 1 |
| Mok, TS | 1 |
| Kraser, CN | 1 |
| Tetrealt, JC | 1 |
| Telatar, M | 1 |
| Malone, R | 1 |
| Bosserman, L | 1 |
| Barstis, J | 1 |
| Grody, WW | 1 |
| Tsirigotis, P | 1 |
| Economopoulos, T | 1 |
| Rontogianni, D | 1 |
| Dervenoulas, J | 1 |
| Papageorgiou, E | 1 |
| Bollas, G | 1 |
| Mantzios, G | 1 |
| Kalantzis, D | 1 |
| Koumarianou, A | 1 |
| Raptis, S | 1 |
| Murohashi, I | 1 |
| Kashimura, T | 1 |
| Tominaga, K | 1 |
| Wakao, D | 1 |
| Takahashi, T | 1 |
| Akiba, M | 1 |
| Kishimoto, K | 1 |
| Yoshida, K | 1 |
| Yagasaki, F | 1 |
| Itoh, Y | 1 |
| Sakata, T | 1 |
| Kawai, N | 1 |
| Itoh, K | 1 |
| Suzuki, T | 1 |
| Matsuda, A | 1 |
| Hirashima, K | 1 |
| Chow, KU | 1 |
| Sommerlad, WD | 1 |
| Boehrer, S | 1 |
| Schneider, B | 1 |
| Seipelt, G | 1 |
| Rummel, MJ | 1 |
| Hoelzer, D | 1 |
| Mitrou, PS | 1 |
| Weidmann, E | 1 |
| Siemens, HJ | 1 |
| Gerke, P | 1 |
| Steinhoff, J | 1 |
| Roth-Isigkeit, A | 1 |
| Wagner, K | 1 |
| Brückner, S | 1 |
| Weide, R | 1 |
| Heymanns, J | 1 |
| Gores, A | 1 |
| Köppler, H | 1 |
| Heilig, B | 1 |
| Mapara, M | 1 |
| Bargou, R | 1 |
| Fiehn, C | 1 |
| Dörken, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy[NCT01626352] | Phase 2 | 22 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as the time from date of first documented confirmed response to date of disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. Patients who begin further anticancer therapy prior to disease progression will be censored at the date of last tumor assessment prior to the start date of the anticancer therapy. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle and every 3 months thereafter until disease progression or relapse from complete response for up to 38 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 5.6 |
Disease response assessments will be performed using the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires a disappearance of all evidence of disease. (NCT01626352)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 7 |
A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and up to 30 days after last dose, projected 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 16 |
Overall response is the number of patients with observed complete or partial response (CR or PR) as assessed using the International Working Group (IMW) revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires disappearance of all evidence of disease. Partial response requires regression of measurable disease and no new sites. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter, projected 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 19 |
Defined as the time from Day 1 of study drug administration to date of death from any cause. (NCT01626352)
Timeframe: every 3 cycles during treatment and every 3 months thereafter until progression or death from any cause, projected 18 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 12.0 |
Defined as the time from first treatment until objective tumor progression, relapse from complete response, or death from any cause. Tumor response is defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 8.6 |
Defined as the time from date of first treatment to the date of first documented disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 10.5 |
1 review available for mitoxantrone and Lymphoma, B-Cell
| Article | Year |
|---|---|
Pixantrone beyond monotherapy: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Isoquinolines | 2019 |
8 trials available for mitoxantrone and Lymphoma, B-Cell
| Article | Year |
|---|---|
Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Dexamethasone; | 2015 |
Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2011 |
A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2003 |
Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2004 |
Phase II study of the CPT-11, mitoxantrone and dexamethasone regimen in combination with rituximab in elderly patients with relapsed diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2006 |
Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineo | 2001 |
Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamid | 2002 |
Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2002 |
21 other studies available for mitoxantrone and Lymphoma, B-Cell
| Article | Year |
|---|---|
Polysialylated nanoinducer for precisely enhancing apoptosis and anti-tumor immune response in B-cell lymphoma.
Topics: Animals; Apoptosis; Immunity; Lymphoma; Lymphoma, B-Cell; Mice; Mitoxantrone | 2022 |
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Humans | 2018 |
Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2003 |
Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineopla | 2003 |
Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dis | 2003 |
Rituximab in a patient with acute renal failure due to B-cell lymphomatous infiltration of the kidneys.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineop | 2004 |
An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti- | 2005 |
Non-Hodgkin disease in beta-thalassemia major.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta-Thalassemia; Child; Child, Preschool; Co | 2006 |
Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans | 2006 |
[A case of secondary malignant lymphoma of the urinary bladder].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 2006 |
[Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2007 |
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italian
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Co | 2007 |
[Combination chemotherapy with BH-AC, mitoxantrone, etoposide, and prednisolone to refractory or relapsed malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedul | 1997 |
Autologous bone marrow transplantation versus MACOP-B in B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Thera | 1997 |
Excellent tolerance of rituximab when given after mitoxantrone/cyclophosphamide: an effective and safe combination for indolent non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2000 |
T-cell-rich B-cell lymphoma. Analysis of clinical features, response to treatment, survival and comparison with diffuse large B-cell lymphoma.
Topics: Aged; Antigens, CD; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 2001 |
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Der | 2002 |
A prolonged APTT in a patient with a low grade malignant NHL - a case report.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Blood Coagulation Factors; C | 2002 |
TNF alpha therapy activates human B-lymphoma cells in vivo and may protect myelopoiesis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bone Marrow; Cytarabine; Femal | 1992 |